Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence

C. Belluco, G. Esposito, R. Bertorelle, R. Alaggio, L. Giacomelli, L. C. Bianchi, D. Nitti, M. Lise

Research output: Contribution to journalArticlepeer-review


Aims: Fas ligand (FasL) expression by cancer cells may mediate tumour immune privilege. The purpose of the present study was to investigate the timing and significance of FasL expression during the colorectal adenoma-carcinoma sequence. Methods: FasL expression was studied by immunohistochemistry in 170 formalin-fixed tissue sections representing the entire colorectal adenoma-carcinoma sequence. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to search for FasL mRNA. Analysis of survival was performed in patients with carcinomas. Results: A significant positive linear correlation was found between FasL expression and tumour progression throughout the colorectal adenoma-carcinoma sequence (rs=0.677; P

Original languageEnglish
Pages (from-to)120-125
Number of pages6
JournalEuropean Journal of Surgical Oncology
Issue number2
Publication statusPublished - Mar 2002


  • Adenoma-carcinoma sequence
  • Colorectal cancer
  • Fas ligand

ASJC Scopus subject areas

  • Oncology
  • Surgery


Dive into the research topics of 'Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence'. Together they form a unique fingerprint.

Cite this